Anavex Life Sciences Corp (AVXL)

[polarbear77]

I don’t know about the quarterly call, but what I do know is that if we receive an approval for just one indication, then physicians and patients will be writing and filling off-label prescriptions for blarcamesine around the world for dementia-related diseases in short order.

Especially if they are made aware of the below and if their physicians also compare the safety profiles of blarcamesine and current SOC drugs or aducanumab.

“Change in MMSE score from baseline at week 104 of matched cohorts was assessed. It showed that ANAVEX®2-73 (blarcamesine) high dose cohort had a significantly lower MMSE decline (-1.1) compared to the ADNI control cohort (-4.4) at week 104 (p < 0.01).”

So, regulators in the US have already granted 2-73 (blarcamesine) ODD Designation and Rare Pediatric Disease Designation and now this week, Fast Track Designation, for Rett Syndrome disorder.

That’s no guarantee of success, but someone appears to like what they see.

And it’s not just our CMO and RS trial PI Dr Walter Kaufmann. The same gentleman who literally wrote the book on Rett Syndrome current diagnostic guidelines and the first clinical textbook on the disorder during the course of his distinguished career.


https://www.anavex.com/anavex-life-sciences-announces-the-appointment-of-walter-e-kaufmann-md-as-chief-medical-officer/